Log has written
TUESDAY, FEBRUARY 14, 2012

PTI

Mumbai: Piramal Healthcare has acquired blood plasma products of Germany-based PlasmaSelect AG for an undisclosed amount.

“The company announced the completion of a definitive agreement with PlasmaSelect to acquire its polygeline-based blood plasma products marketed under the brand name ‘Haemaccel´ in over 38 countries,” Piramal Healthcare said in a filing to the Bombay Stock Exchange.

Blood plasma expansion products are infusion pharmaceuticals that help maintain blood plasma volume until blood transfusion can be administered to the patient, in the event of blood loss.

“The acquisition is intended to bring global leadership to Piramal Healthcare’s polygeline-based blood plasma products expansion,” the filing added.

At present, Piramal Healthcare, formerly Nicholas Piramal, markets the products under ‘Haemaccel´ brand name in India and ‘Haemageline´ in 17 other countries.

The annual revenue of Haemaccel and associated brands of Piramal Healthcare and PlasmaSelect together are around Rs62 crore.

Shares of Piramal Healthcare closed at Rs305.80, up 1.58% on the BSE.

Tags - Find More Articles On:
blog comments powered by Disqus
Tata Motors Q3 net up 41% on strong JLR sales
Net profit Rs3,406 crore vs market forecast Rs2,613 crore; revenue rises 44% to Rs45,260 crore; shares...
Views | Recession signals on the high seas?
The crash in shipping rates is no longer a good indicator of an incipient downturn
Views | India’s fiscal headache
India cannot bank infinitely upon growth for fiscal deliverance
Views | Still mired in caste politics
Caste politics has become even more important in recent decades, especially after the collapse of mass...
Moody’s warns may cut AAA-rating for UK and France
Germany, EFSF triple-A rating unchanged; UK top-tier rating at risk by a major agency for first time;...